Understand · Treat · Recover
Types of Ovarian Cancer
The pathology subtype helps determine which treatments are likely to work.
This guide is educational and does not replace individual medical assessment. Do not start, stop or change treatment without the treating team. Cancer Aware supports patients and families worldwide. Drug approvals, availability, affordability and care pathways vary by country.
Chapter 4 of 20
The main families
| Family | Examples | Why it matters |
|---|---|---|
| Epithelial | High-grade serous, low-grade serous, endometrioid, clear-cell, mucinous | The largest group, with important differences within it. |
| Germ-cell | Dysgerminoma, yolk-sac tumour, immature teratoma | Often affects younger people; treatment and tumour markers differ. |
| Sex-cord stromal | Granulosa-cell and other stromal tumours | May produce hormones and require prolonged follow-up. |
| Borderline | Serous or mucinous borderline tumour | Not managed as ordinary invasive epithelial cancer. |
High grade and low grade are different biology
Grade describes microscopic features, not how far cancer has spread. High-grade serous cancer often responds to initial platinum chemotherapy. Low-grade serous cancer is usually slower-growing but less chemotherapy-sensitive; surgery, hormone treatment and selected targeted drugs may have important roles. Low grade does not mean that follow-up is unnecessary.
Confirm the origin when the diagnosis is unusual
A mucinous tumour in an ovary can be a primary ovarian cancer or a metastasis from another organ, such as the bowel or appendix. Pathology review, imaging and selected additional tests help distinguish these possibilities. A second specialist pathology opinion is useful when the sample is limited, the diagnosis is rare or the clinical findings do not fit.
Read the report with the team
- Ask for the histological type, grade and site of origin.
- Separate borderline from invasive disease.
- Ask whether additional staining or molecular testing could change the plan.
Key takeaway
Always link treatment advice to the confirmed subtype.
Common questions
Are all ovarian cancers treated alike?
No. Subtype, stage, molecular results and fitness all affect treatment.
Is low grade the same as stage I?
No. Grade is a tissue feature; stage is the extent of spread.
Can a borderline tumour recur?
Yes. Follow-up remains important even when the initial outlook is excellent.
Do germ-cell tumours use CA-125 alone?
No. AFP, beta-hCG or LDH may be useful depending on the subtype.
Why seek a pathology review?
It can resolve uncertainty and prevent treatment being chosen for the wrong tumour family.